DRC facing decline in donor funding, HIV treatment shortage

"The lives of thousands of HIV-positive people in the Democratic Republic of Congo (DRC) are at risk as the country faces declining donor funding and a severe shortage of HIV treatment, according to Medecins Sans Frontieres (MSF)," PlusNews reports. "'The problem is quite old in the DRC; the country has always been minimized by donors who have not seen it as a priority, mainly because HIV prevalence is relatively low at between three and four percent,' Thierry Dethier, advocacy manager for MSF Belgium in the DRC, told IRIN/PlusNews," and he added, "But look at the indicators: more than one million people are living with HIV, 350,000 of whom qualify for [antiretrovirals (ARVs)] but only 44,000 -- or 15 percent -- are on ARVs," the news service writes.

The news service cites "the end of six years of World Bank funding in 2011"; the end of UNITAID funding, which provides for pediatric and second-line ARVs, in December 2012; and "the cancellation of Round 11 funding by the Global Fund to Fight AIDS, Tuberculosis and Malaria" as reasons for the ARV shortage in the DRC. "The Global Fund says it is reviewing a request for continued funding, and no life-saving programs will be cut as a result of funding shortages," but "Dethier noted that other donors would have to step up their funding," the news service writes (2/2).


http://www.kaiserhealthnews.orgThis article was reprinted from kaiserhealthnews.org with permission from the Henry J. Kaiser Family Foundation. Kaiser Health News, an editorially independent news service, is a program of the Kaiser Family Foundation, a nonpartisan health care policy research organization unaffiliated with Kaiser Permanente.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
New insights into the mechanisms of efavirenz-induced neurotoxicity